RetinAI
its AI-based OCT analytics platform (RetinAI Discovery) was acquired by EssilorLuxottica, a transaction reported in October 2025, positioning the technology within a much larger eye-health and eyewear business.
- Country
- Switzerland
Commercial
RetinAI Discovery OCT analytics
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI optical coherence tomography screening | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.